Minor changes since publication
July 2018: The Fracture Liaison Service Database has been added to the data sources for measures in statements 1, 2 and 3.
October 2017: Information about drug licensing for bisphosphonate and non-bisphosphonate drugs has been included in the definitions sections for statements 2 and 3.
June 2017: The definition of drug treatment to reduce fracture risk in quality statements 2 and 3 has been updated to remove reference to strontium ranelate. This change has been made in order to match the National Osteoporosis Guideline Group's Clinical guideline for the prevention and treatment of osteoporosis.